This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Kummalue, T.
Right arrow Articles by Friedman, A. D.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Kummalue, T.
Right arrow Articles by Friedman, A. D.

 Previous Article  |  Next Article 

Molecular and Cellular Biology, December 2002, p. 8278-8291, Vol. 22, No. 23
0270-7306/02/$04.00+0     DOI: 10.1128/MCB.22.23.8278-8291.2002
Copyright © 2002, American Society for Microbiology. All Rights Reserved.

Multimerization via Its Myosin Domain Facilitates Nuclear Localization and Inhibition of Core Binding Factor (CBF) Activities by the CBFß-Smooth Muscle Myosin Heavy Chain Myeloid Leukemia Oncoprotein

Tanawan Kummalue, Jianrong Lou, and Alan D. Friedman*

Division of Pediatric Oncology, Johns Hopkins University, Baltimore, Maryland

Received 30 May 2002/ Returned for modification 19 August 2002/ Accepted 26 August 2002

In CBFß-SMMHC, core binding factor beta (CBFß) is fused to the {alpha}-helical rod domain of smooth muscle myosin heavy chain (SMMHC). We generated Ba/F3 hematopoietic cells expressing a CBFß-SMMHC variant lacking 28 amino acids homologous to the assembly competence domain (ACD) required for multimerization of skeletal muscle myosin. CBFß-SMMHC({Delta}ACD) multimerized less effectively than either wild-type protein or a variant lacking a different 28-residue segment. In contrast to the control proteins, the {Delta}ACD mutant did not inhibit CBF DNA binding, AML1-mediated reporter activation, or G1 to S cell cycle progression, the last being dependent upon activation of CBF-regulated genes. We also linked the CBFß domain to 149 or 83 C-terminal CBFß-SMMHC residues, retaining 86 or 20 amino acids N-terminal to the ACD. CBFß-SMMHC(149C) multimerized and slowed Ba/F3 proliferation, whereas CBFß-SMMHC(83C) did not. The majority of CBFß-SMMHC and CBFß-SMMHC(149C) was detected in the nucleus, whereas the {Delta}ACD and 83C variants were predominantly cytoplasmic, indicating that multimerization facilitates nuclear retention of CBFß-SMMHC. When linked to the simian virus 40 nuclear localization signal (NLS), a significant fraction of CBFß-SMMHC({Delta}ACD) entered the nucleus but only mildly inhibited CBF activities. As NLS-CBFß-SMMHC(83C) remained cytoplasmic, we directed the ACD to CBF target genes by linking it to the AML1 DNA binding domain or to full-length AML1. These AML1-ACD fusion proteins did not affect Ba/F3 proliferation, in contrast to AML1-ETO, which markedly slowed G1 to S progression dependent upon the integrity of its DNA-binding domain. Thus, the ACD facilitates inhibition of CBF by mediating multimerization of CBFß-SMMHC in the nucleus. Therapeutics targeting the ACD may be effective in acute myeloid leukemia cases associated with CBFß-SMMHC expression.

* Corresponding author. Mailing address: Johns Hopkins University, Cancer Research Building, Room 253, 1650 Orleans Street, Baltimore, MD 21231. Phone: (410) 955-2095. Fax: (410) 955-8897. E-mail: afriedm2{at}jhem.jhmi.edu.

Molecular and Cellular Biology, December 2002, p. 8278-8291, Vol. 22, No. 23
0022-538X/02/$04.00+0     DOI: 10.1128/MCB.22.23.8278-8291.2002
Copyright © 2002, American Society for Microbiology. All Rights Reserved.



This article has been cited by other articles:

  • Wee, H.-J., Voon, D. C.-C., Bae, S.-C., Ito, Y. (2008). PEBP2-{beta}/CBF-{beta}-dependent phosphorylation of RUNX1 and p300 by HIPK2: implications for leukemogenesis. Blood 112: 3777-3787 [Abstract] [Full Text]  
  • Wunderlich, M., Krejci, O., Wei, J., Mulloy, J. C. (2006). Human CD34+ cells expressing the inv(16) fusion protein exhibit a myelomonocytic phenotype with greatly enhanced proliferative ability. Blood 108: 1690-1697 [Abstract] [Full Text]  
  • Huang, G., Shigesada, K., Wee, H.-J., Liu, P. P., Osato, M., Ito, Y. (2004). Molecular basis for a dominant inactivation of RUNX1/AML1 by the leukemogenic inversion 16 chimera. Blood 103: 3200-3207 [Abstract] [Full Text]  
  • Bernardin-Fried, F., Kummalue, T., Leijen, S., Collector, M. I., Ravid, K., Friedman, A. D. (2004). AML1/RUNX1 Increases During G1 to S Cell Cycle Progression Independent of Cytokine-dependent Phosphorylation and Induces Cyclin D3 Gene Expression. J. Biol. Chem. 279: 15678-15687 [Abstract] [Full Text]  
  • Durst, K. L., Lutterbach, B., Kummalue, T., Friedman, A. D., Hiebert, S. W. (2003). The inv(16) Fusion Protein Associates with Corepressors via a Smooth Muscle Myosin Heavy-Chain Domain. Mol. Cell. Biol. 23: 607-619 [Abstract] [Full Text]  


Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»